Home › Mantle Cell Lymphoma › Texas › Houston
Mantle Cell Lymphoma clinical trials in Houston, TX
15 studies for Mantle Cell Lymphoma are looking for participants at sites in and around Houston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
RecruitingPhase 1/2
- Research Site, Houston
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
RecruitingPhase 3
- Md Anderson Cancer Center, Houston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
- Md Anderson Cancer Center, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RecruitingPhase 1/2
- Research Site, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
RecruitingPhase 1
- The University of TX MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
RecruitingPhase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
RecruitingPhase 2
- M D Anderson Cancer Center, Houston
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
RecruitingPhase 2Healthy volunteers welcome
- MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
- MD Anderson Cancer Center, Houston
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
RecruitingPhase 1
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Houston
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
RecruitingPhase 2
- M D Anderson Cancer Center, Houston
Mantle Cell Lymphoma trials in other cities
- Baldwin Park, CA15 studies
- Durham, NC13 studies
- New York City, NY12 studies
- Milwaukee, WI12 studies
- Seattle, WA12 studies
- Boston, MA11 studies
- Columbus, OH11 studies
- Nashville, TN11 studies
- Chicago, IL10 studies
- Portland, OR9 studies
- Rochester, MN9 studies
- St. Louis, MO8 studies
Other studies in Houston
- Non-Small Cell Lung Cancer145 studies
- Breast Cancer126 studies
- Cancer (all types)121 studies
- Metastatic Cancer104 studies
- Colorectal Cancer102 studies
- Ovarian Cancer89 studies
- Acute Myeloid Leukemia85 studies
- Lung Cancer78 studies
- Prostate Cancer76 studies
- Endometrial Cancer68 studies
- Pancreatic Cancer61 studies
- Melanoma59 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.